[Bronchial tuberculosis in the elderly: apropos of 9 cases. Radioclinical, endoscopic and developmental aspects]. / Tuberculose bronchique chez la personne âgée: à propos de neuf cas. Aspects radiocliniques, endoscopiques et évolutifs.

We report nine cases of elderly French patients (more than 65 years old) with bronchial tuberculosis. We report the clinical features, radiological and endoscopic aspects. The symptoms are non specific and may delay the diagnostic. The chest X-ray and endoscopic aspects are tumor like. Retractile bronchial stenosis is a potential evolution.

[Bullous manifestations of Kaposi disease associated with AIDS]. / Manifestations bulleuses d'une maladie de Kaposi associee au SIDA.

INTRODUCTION: We report the apparently first description of bullous Kaposi's sarcoma in a patient with AIDS. CASE REPORT: Kaposi's sarcoma was observed in a HIV positive homosexual who had developed AIDS. The delay between the development of Kaposi's sarcoma and the appearance of bullae was 6 months. Bullae occurred after oedema and necrosis of the subepidermic derma. DISCUSSION: This unusual clinical presentation of Kaposi's syndrome in an AIDS patient led to rapid tumor extention and would thus suggest a rapidly unfavourable prognosis.

[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]. / Porphyrie cutanée tardive induite par des inhibiteurs de l'HMGCoA réductase: simvastatine, pravastatine.

INTRODUCTION: Based on experimental data, HMG CoA reductase inhibitors are theoretically contraindicated in patients with porphyria. These new cholesterol lowering drugs are increasingly being prescribed. We report the first case of drug-related porphyria cutanea tarda due to HMG CoA reductase inhibitors. CASE REPORT: Porphyria cutanea tarda was diagnosed in a patient with chronic alcoholism 18 months after beginning a treatment with simvastatin followed by pravastatin. These drugs were given under different trade names and reintroduced successively leading to acute episodes. Total withdrawal of HMG CoA reductase inhibitors was followed by clinical normalization. COMMENTS: This case confirmed the theoretical contraindication for the use of HMG CoA reductase inhibitors in patients with porphyria. The risk of revealing porphyria with this type of cholesterol lowering drugs is emphasized. Since these drugs are used very frequently, similar cases may well be reported soon.